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Arterial stiffness & Sri Lankan 
chronic kidney disease of unknown 
origin
Fiona Gifford1,2, Robert Kimmitt1, Chula Herath3, David J Webb1, Vanessa Melville1, 
Sisira Siribaddana4, Michael Eddleston1,2 & Neeraj Dhaun1,5
Chronic kidney disease (CKD) is common and independently associated with cardiovascular disease 
(CVD). Arterial stiffness contributes to CVD risk in CKD. In many developing countries a considerable 
proportion of CKD remains unexplained, termed CKDu. We assessed arterial stiffness in subjects 
with Sri Lankan CKDu, in matched controls without CKD and in those with defined CKD. Aortic blood 
pressure (BP), pulse wave velocity (PWV) and augmentation index (AIx) were assessed in 130 subjects 
(50 with CKDu, 45 with CKD and 35 without CKD) using the validated TensioMed™ Arteriograph 
monitor. Brachial and aortic BP was lower in controls than in CKDu and CKD subjects but no different 
between CKDu and CKD. Controls had a lower PWV compared to subjects with CKDu and CKD. Despite 
equivalent BP and renal dysfunction, CKDu subjects had a lower PWV than those with CKD (8.7 ± 1.5 vs. 
9.9 ± 2.2 m/s, p < 0.01). Excluding diabetes accentuated the differences in PWV seen between groups 
(controls vs. CKDu vs. CKD: 6.7 ± 0.9 vs. 8.7 ± 1.5 vs. 10.4 ± 1.5 m/s, p < 0.001 for all). Sri Lankan CKDu 
is associated with less arterial stiffening than defined causes of CKD. Whether this translates to lower 
cardiovascular morbidity and mortality long term is unclear and should be the focus of future studies.
Chronic kidney disease (CKD) is a significant cause of morbidity and mortality worldwide1. In many developing 
countries a considerable proportion of CKD remains unexplained by traditional risk factors. This is often called 
chronic kidney disease of unknown etiology (CKDu). CKDu is a diagnosis of exclusion, made when a patient 
fulfills the Kidney Disease Improving Global Outcomes (KDIGO) CKD criteria but without evidence of a rec-
ognized cause such as diabetes, hypertension, or glomerulonephritis2. Over the last decade CKDu has become a 
leading cause of death in Sri Lanka3.
CKD is an independent risk factor for cardiovascular disease (CVD)4. Increased arterial stiffness, as measured 
by pulse wave velocity (PWV), is a characteristic feature of CKD5, a recognised marker of CVD risk5,6, and an 
independent predictor of mortality and survival in CKD6,7. To date, there have been no studies of arterial stiffness 
in those with pre-dialysis CKDu. Furthermore, it remains unclear whether the CVD risk associated with CKDu 
is the same as that of CKD of known cause. We hypothesised that CKDu patients would have increased arterial 
stiffness compared to matched controls but that these measures would be no different compared to matched sub-
jects with defined aetiologies for their CKD.
Materials & Methods
This was a prospective, cross-sectional case controlled study performed in Anuradhapura, North Central 
Province and Colombo, Sri Lanka with approval of the Ethics Review Committee, Faculty of Medicine & Allied 
Sciences, Rajarata University of Sri Lanka and the written informed consent of each subject. The investigations 
conformed to the principles outlined in the Declaration of Helsinki.
Subjects. Subjects were aged between 18 and 85 years. Chronic kidney disease of unknown origin 
(CKDu) was defined as evidence of renal dysfunction (proteinuria or Chronic Kidney Disease Epidemiology 
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Collaboration (CKD-EPI) eGFR < 60 ml/min/1.73 m2) with no clear aetiological factor (history of diabetes mel-
litus, long-standing hypertension–defined as a BP ≥ 160/100 mmHg untreated or ≥ 140/90 mmHg whilst taking 
antihypertensive medication, history of known renal disease). The diagnosis of CKD was based on the same cri-
teria but with an established cause for the renal impairment. A group of age- and sex-matched controls were also 
recruited from the same geographical area.
Study protocol. Following a 10 min rest period measurements of BP and arterial stiffness were taken with 
the TensioMed™ Arteriograph monitor (TensioMed Ltd, Hungary). Measurements were taken as the average of 
two readings. The Arteriograph utilises brachial pulse oscillations to calculate aortic pulse wave velocity (PWV), 
augmentation index (AIx), systolic BP and pulse pressure. It also records brachial systolic BP and diastolic BP. 
The Arteriograph has been validated against an invasive measure of aortic PWV8 and two commonly used 
non-invasive measurement devices, the Complior and SphygmoCor9,10.
Blood was sampled routinely for serum creatinine. Creatinine clearance, as an estimate of GFR, was calculated 
according to the CKD-EPI equation11.
Statistical analysis. There are no previous studies of pre-dialysis CKDu with which we could perform a 
power calculation. Thus, based on data from previous studies in western populations12,13 we aimed to recruit 
at least 30 subjects into each of the 3 groups. Data were stored and statistical analysis performed using Graph 
Pad Prism, version 6.0 (Graph Pad Software Inc. San Diego, California). Data are presented as mean ± standard 
deviation (SD). Differences between groups were assessed using ordinary one-way ANOVA with Tukey’s multiple 
comparisons post-hoc test. Statistical significance was taken at the 5% level.
Results
Subject characteristics are shown in Table 1. The 3 groups were well matched. However, there were fewer smokers 
in both CKD groups than in the control group, and those with CKD had a modestly higher body mass index 
(BMI) than those with CKDu. As expected, brachial and aortic blood pressure (BP) was lower in controls than 
Parameter
Controls 
(n = 35)
CKDu 
(n = 50)
CKD 
(n = 45)
Demographic
 Age, years 56 ± 9 58 ± 10 61 ± 11
 Male sex, n (%) 24 (69) 35 (70) 34 (76)
 Current smoker (%) 17 (49) 6 (12) 4 (8)
Clinical
 BMI, kg/m2 22 ± 5 22 ± 4 24 ± 4**
 Brachial blood pressure, mmHg
 Systolic 121 ± 20* 131 ± 22 135 ± 15
 Diastolic 73 ± 11* 79 ± 12 81 ± 11
 Creatinine, μ mol/L 77 ± 13**** 434 ± 380 292 ± 143
CKD stage
 1 — 0 0
 2 — 0 0
 3 — 17 17
 4 — 11 16
 5 — 22 12
 Estimated GFR, mL/min /1.73m2 89 ± 16**** 23 ± 17 24 ± 13
 Hypertension (%) 18 (51) 34 (68) 31 (69)
 Diabetes mellitus (%) 16 (46) 0 (0) 22 (49)
Medications, n (%)
 α -blocker 2 (6) 8 (16) 7 (16)
 ACE inhibitor 8 (23) 32 (64) 29 (64)
 ARB 3 (9) 36 (72) 32 (71)
 β -blocker 7 (20) 20 (40) 18 (40)
 Calcium channel blocker 6 (17) 18 (36) 21 (47)
 Diuretic 2 (6) 31 (62) 27 (69)
 Statin 16 (46) 0 (0) 22 (49)
Table 1. Study participant data–all subjects. Values are given as mean ± SD (%). ACE: angiotensin converting 
enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; CKD: chronic kidney disease; CKDu: 
chronic kidney disease of unknown origin; DBP: diastolic BP; eGFR: estimated glomerular filtration rate; SBP: 
systolic BP. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used to compare baseline 
characteristics between all groups.*p < 0.05 vs. CKDu and vs. CKD, **p < 0.01 vs. CKDu, ****p < 0.0001 vs. CKDu 
and vs. CKD.
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in CKDu and CKD subjects. Importantly, CKDu and CKD subjects did not differ in terms of brachial or aortic 
BP components (Fig. 1A,B). Interestingly, in the face of equivalent BP and degree of renal dysfunction, those 
with CKDu had a ~15% lower PWV than those with CKD (Fig. 1C,D). Aortic augmentation index (AIx) was no 
different between the 2 groups.
Figure 1. Aortic systolic BP (SBP) (A), aortic pulse pressure (PP) (B), aortic pulse wave velocity (PWV)  
(C) and aortic augmentation index (AIx) (D) in control subjects, those with CKDu and CKD. Horizontal black 
line represents mean. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used to compare 
all groups.
Parameter Controls(n = 19) CKDu(n = 50) CKD(n = 23)
Demographic
 Age, years 54 ± 10* 58 ± 10 62 ± 12
 Male sex, n (%) 13 (68) 35 (70) 16 (70)
 Current smoker (%) 10 (53) 6 (12) 0 (0)
Clinical
 BMI, kg/m2 22 ± 4 22 ± 4 25 ± 4**
Brachial blood pressure, mmHg
 Systolic 120 ± 16* 131 ± 22 136 ± 16
 Diastolic 72 ± 9* 79 ± 12 81 ± 14
 Creatinine, μ mol/L 76 ± 16**** 434 ± 380 287 ± 132
 Estimated GFR, mL/min /1.73m2 91 ± 19**** 23 ± 17 24 ± 13
 Hypertension (%) 8 (42) 34 (68) 13 (57)
Table 2. Study participant data – subjects with diabetes excluded. Values are given as mean ± SD (%). BMI: 
body mass index; CKD: chronic kidney disease; CKDu: chronic kidney disease of unknown origin; DBP: 
diastolic BP; eGFR: estimated glomerular filtration rate; SBP: systolic BP. Ordinary one-way ANOVA with 
Tukey’s multiple comparisons test was used to compare baseline characteristics between all groups.*p < 0.05 vs. 
CKD, **p < 0.01 vs. CKDu, ****p < 0.0001 vs. CKDu and vs. CKD.
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Hypertension and diabetes are both important contributors to arterial stiffness14. Although the number of 
subjects with hypertension was similar in the CKDu and CKD groups, diabetes was only present in those with 
CKD. Thus, we re-analysed our measures of arterial stiffness excluding those with diabetes. This did not affect 
differences between groups in terms of age, BMI, BP, degree of renal dysfunction or prevalence of hypertension 
(Table 2 and Fig. 2A,B). Importantly, the absence of diabetes accentuated the differences in PWV seen between 
groups – subjects with CKDu had a ~30% higher PWV than matched controls; PWV in those with CKD was 
~20% higher than that associated with CKDu (Fig. 2C,D).
Discussion
To our knowledge this is the first study exploring arterial stiffness in a population of Sri Lankan subjects with 
CKDu. In keeping with other studies from developed countries we have found that those with CKD have a higher 
PWV than those without CKD15. This is important because PWV is an established independent predictor of 
mortality and survival in CKD6,7 and is also modifiable16. Our control group, who had an estimated glomerular 
filtration rate (eGFR) > 60 ml/min/1.73 m2, had comparable PWV values to those seen in other similar cohorts 
both in the presence12 and absence13 of diabetes.
Most noteworthy was our finding that, despite similar eGFR and BP, those with CKDu had a lower PWV than 
those with a defined cause for CKD. CKDu is primarily a disorder of the tubulointerstitium whereas most causes 
of CKD primarily affect the glomeruli (IgA nephropathy, diabetes, hypertension). A few studies17 suggest arterial 
stiffness in CKD may vary by underlying etiology and our data add to these. Furthermore, one study in subjects 
with end-stage renal failure due to Balkan nephropathy (an endemic nephropathy similar to Sri Lankan CKDu), 
investigated arterial stiffness using the same technique as here, and found that PWV was lower than in those with 
other causes for their dialysis-requiring renal failure18. The authors suggested the difference may be due to the 
later occurrence of hypertension in those with Balkan nephropathy, which is also a feature of CKDu in Sri Lanka3.
Although PWV varied significantly between CKD and CKDu we found no difference in AIx. Whilst PWV and 
AIx are both used as surrogate measures of arterial stiffness they are not interchangeable. PWV is an assessment 
of large artery stiffness. AIx is derived from analysis of the pulse contour and is the proportion of central pulse 
pressure that results from arterial wave reflection. Although the timing of the arrival of the reflected wave at the 
Figure 2. Aortic systolic BP (SBP) (A), aortic pulse pressure (PP) (B), aortic pulse wave velocity (PWV)  
(C) and aortic augmentation index (AIx) (D) in control subjects, those with CKDu and CKD, excluding 
subjects with diabetes. Horizontal black line represents mean. Ordinary one-way ANOVA with Tukey’s multiple 
comparisons test was used to compare all groups.
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proximal aorta is largely determined by large artery PWV, AIx is not simply a surrogate measure of PWV. It is 
influenced by vasoactive drugs independently of PWV19, suggesting that it is also determined by the intensity of 
wave reflection which, in turn, is determined by the diameter and elasticity of small arteries and arterioles. AIx 
increases with mean arterial pressure20 and is inversely related to heart rate21 and body height22, so these variables 
should be accounted for when interpreting studies that use pulse contour analysis. In the current study some of 
these factors may account for the lack of difference in AIx between CKD and CKDu as could under-powering of 
the study with respect to this parameter.
Although this is the first study of its kind we recognise a number of limitations. Our study size increases the 
chances of our results being subject to a type II error. Larger similar studies are needed to confirm our findings. 
Furthermore, some of the medications taken by our patients, such as ACE inhibitors, angiotensin receptor block-
ers, and ß blockers may have affected arterial stiffness. However, all patients were stabilised on their therapies 
and the CKD groups were on similar treatments in this respect. We also saw a high prevalence of diabetes in our 
cohort and so our findings may not be generalizable to population outside Sri Lanka. Finally, we were unable to 
assess the influence of proteinuria or other more novel CVD risk factors such as circulating C-reactive protein, 
asymmetric dimethylarginine or endothelin-1, all of which may contribute to arterial stiffening23 and so may, in 
part, explain the differences we are seeing. This was not possible in the current study but should be the focus for 
future work.
Significance. Measures of arterial stiffness are not currently used in the clinic. However, there have been a 
number of clinical studies that have examined differences in PWV between health and disease. We have previ-
ously shown that patients with CKD stage IV – the mean eGFR in the current study fits into this–had a PWV of 
7.0 ± 1.4 m/s compared to 6.2 ± 0.9 m/s in matched controls. This ~13% is difference similar to the magnitude of 
the difference observed here between CKD and CKDu. More importantly, a few clinical trials have demonstrated 
that differential lowering of PWV with medical treatment results in different cardiovascular or renal outcomes24,25 
and the importance of such studies is underscored by epidemiological data that suggest that PWV is an inde-
pendent risk factor for cardiovascular morbidity and mortality6,14,26. Karalliedde et al. have previously shown that 
treatment of patients with type 2 diabetes and proteinuria with 6 months of valsartan/hydrochlorthiazide reduced 
PWV by ~14% (12.5 to 10.7 m/s)27. In the same study the calcium channel blocker amlodipine reduced PWV by 
~6%, a similar effect in magnitude to that seen with endothelin receptor antagonists16.
This is the first study suggesting that Sri Lankan CKDu is associated with less arterial stiffening than other 
defined causes of CKD. There remain a number of unanswered questions that should be the focus of future work: 
what is the natural history of arterial stiffness in CKDu; is this modifiable; and, if so, does this translate to lower 
cardiovascular morbidity and mortality long term compared to other forms of CKD.
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